Persistence of HIV-1 latent reservoir cells during antiretroviral therapy (ART) is a major 23 obstacle for curing HIV-1. Latency-reversing agents (LRAs) are under intensive development to 24 reactivate and eradicate latently infected cells; however, there are a few useful models for 25 evaluating LRA activity in vitro. Here, we established a chronically HIV-1-infected culture 26 system harboring thousands of different HIV-1-infected cell clones with a wide distribution of 27 HIV-1 provirus similar to that observed in vivo. A combination of an LRA and an anti-HIV-1 28 drug successfully inhibited viral re-emergence after drug discontinuation, demonstrating 29 "experimental cure" in the in vitro model. We demonstrated that the epigenetic environment of 30 the integrated provirus plays a role in determining drug susceptibility. Our widely distributed 31 intact provirus elimination (WIPE) assay will be useful for optimizing therapeutics against
INTRODUCTION
that one infected clone was remarkably expanded (Fig. 3g) . Part of the 5ʹLTR, including the 177 transcription start site, in the expanded clone was deleted ( Fig. 3h and Supplementary Fig. 3c ).
178
This may explain the observed lack of virus rebound. In another experiment in which no HIV-1 179 rebound was observed ( Supplementary Fig. 5a and b) , we identified a 1-bp deletion that 180 generated a stop codon in the HIV-1 provirus gag sequence ( Supplementary Fig. 5c and d) .
181
These observations indicate that a combination of EFdA and PEP005 enhances the elimination 182 of intact and replication-competent HIV-1 proviruses, selected only for replication-incompetent 183 proviruses, and thus achieved an experimental cure.
184
We further observed the following underlying mechanisms for replication [28] [29] [30] . We termed this new in vitro selection and elimination assay "the widely distributed long-term antiretroviral treatment also reduced the numbers of replication-incompetent replication-competent HIV-1 proviruses that exist as a minor population in Jurkat/NL cells.
197
Experimental cure achieved in the new in vitro model is associated with reactivation of 198 latent HIV-1 reservoirs. The rationale behind using LRA as an HIV-1 cure is reactivating the 199 latent HIV-1 provirus and inducing cell apoptosis via cytopathic effects or recognition by the 200 host antiviral immunity 4, 7, 11, 12, 31 . We therefore investigated whether the experimental cure 201 observed in the present study was indeed mediated by the reactivation of latent reservoirs.
202
First, we investigated the presence of latent clones in the Jurkat/NL system by 203 infecting Jurkat-LTR-green fluorescent protein (GFP) cells (Jurkat cells stably transfected with 204 a plasmid containing the GFP reporter gene driven by the HIV-1 promoter LTR) with
205
HIV-1 NL4-3 . In this system, Tat expression was monitored by GFP expression. We sorted and 206 stimulated the GFP-negative cell fraction with TNF-α and found that the treatment increased 207 proviral transcription in this fraction ( Fig. 4a,b) , indicating the presence of latent reservoirs in 208 the Jurkat/NL system. The percentage of such reservoir cells was determined to be 209 approximately 1% (Fig. 4c ). Since antiviral cytotoxic T-lymphocytes (CTLs) and antibodies are 210 absent in the Jurkat/NL system, latent HIV-1-infected cells reactivated by PEP005 would have 211 been eliminated mainly by viral cytopathicity or cell apoptosis ( Supplementary Fig. 1c ) 10-12 . 212 Therefore, we examined intracellular p24 levels and cell apoptosis during the early phase of 213 drug treatment and observed an increase in p24 protein expression in cells treated with PEP005 214 (+/− EFdA) just 6 h after drug treatment initiation ( Fig. 4d) , which was followed by an increase point. Collectively, these data indicate that the experimental cure achieved in this study was at 229 least partially due to the reactivation of latent HIV-1 reservoirs in the WIPE assay.
231
Genetic and epigenetic environment of the HIV-1 provirus impacts its drug susceptibility 232 in the novel in vitro model. We next investigated whether the drug susceptibility of various 233 clones depends on the genetic and epigenetic environments of the HIV-1 provirus 32 . The 234 proportion of ISs in the host genes was slightly decreased in EFdA-or EFdA + PEP005-treated 235 cells ( Fig. 5a) . Changes in the epigenetic features of HIV-1 ISs during the initial phase of drug 236 treatment were also apparent ( Fig. 5b) . (Fig. 5c ). In addition, HIV-1 262 preferentially integrates into gene bodies with active transcription, resulting in a high proportion 263 of HIV-1 integration within the host gene body 33 (Fig. 1f) . Transcriptional interference between 264 the host genes and integrated proviruses is another factor that affects proviral transcription 34, 35 .
265
In line with this notion, a recent study reported that there is a higher proportion of intact Supplementary Fig. 3a) Extended Data Fig. 5⎮ An underlying mechanism of an experimental cure (Exp. 7) . a, Treatment of Jurkat/NL cells with EFdA (Exp. 7). In this experiment, HIV-1 rebound was not observed in cells treated with EFdA until week 23; however, EFdA-treated cells showed an increase in HIV-1 mRNA expression with TNF-α stimulation (b), suggesting that the cells containing replication-competent proviruses are a minor population. c, PCR products (9031 bp) of cell samples from Exp. 7 on week 23. d, Sequencing analysis of PCR products (#1) in (c) with NGS demonstrated that there is a 1-bp deletion with a premature stop codon in HIV-1 gag. 
